Providing a diverse range of perspectives from bullish to bearish, 29 analysts have published ratings on UnitedHealth Group UNH in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 21 | 2 | 1 | 0 |
| Last 30D | 0 | 2 | 0 | 0 | 0 |
| 1M Ago | 2 | 10 | 2 | 1 | 0 |
| 2M Ago | 3 | 9 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $448.07, a high estimate of $660.00, and a low estimate of $270.00. This current average represents a 21.7% decrease from the previous average price target of $572.24.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of UnitedHealth Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Mok | Barclays | Lowers | Overweight | $350.00 | $362.00 |
| Matthew Gillmor | Keybanc | Lowers | Overweight | $400.00 | $450.00 |
| Sidharth Sahoo | HSBC | Lowers | Reduce | $270.00 | $490.00 |
| Justin Lake | Wolfe Research | Lowers | Outperform | $390.00 | $501.00 |
| Ryan Langston | TD Securities | Lowers | Hold | $308.00 | $520.00 |
| David Macdonald | Truist Securities | Lowers | Buy | $360.00 | $580.00 |
| Ann Hynes | Mizuho | Lowers | Outperform | $350.00 | $515.00 |
| Ben Hendrix | RBC Capital | Lowers | Outperform | $355.00 | $525.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $362.00 | $513.00 |
| Lisa Gill | JP Morgan | Lowers | Overweight | $405.00 | $525.00 |
| George Hill | Deutsche Bank | Lowers | Buy | $362.00 | $521.00 |
| Michael Wiederhorn | Oppenheimer | Lowers | Outperform | $400.00 | $600.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $351.00 | $677.00 |
| Ricky Goldwasser | Morgan Stanley | Lowers | Overweight | $374.00 | $563.00 |
| Kevin Fischbeck | B of A Securities | Lowers | Neutral | $350.00 | $560.00 |
| Michael Ha | Baird | Lowers | Outperform | $356.00 | $510.00 |
| Matthew Gillmor | Keybanc | Lowers | Overweight | $450.00 | $575.00 |
| Michael Ha | Baird | Lowers | Outperform | $510.00 | $640.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $513.00 | $560.00 |
| Lisa Gill | JP Morgan | Lowers | Overweight | $525.00 | $652.00 |
| Ben Hendrix | RBC Capital | Lowers | Outperform | $525.00 | $655.00 |
| Ricky Goldwasser | Morgan Stanley | Lowers | Overweight | $563.00 | $664.00 |
| David Macdonald | Truist Securities | Lowers | Buy | $580.00 | $660.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $560.00 | $642.00 |
| Tim Rezvan | Keybanc | Lowers | Overweight | $575.00 | $650.00 |
| John Ransom | Raymond James | Lowers | Strong Buy | $540.00 | $635.00 |
| Michael Wiederhorn | Oppenheimer | Lowers | Outperform | $600.00 | $640.00 |
| David Macdonald | Truist Securities | Raises | Buy | $660.00 | $610.00 |
| Ann Hynes | Mizuho | Raises | Outperform | $650.00 | $600.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UnitedHealth Group. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of UnitedHealth Group compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of UnitedHealth Group's stock. This analysis reveals shifts in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of UnitedHealth Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on UnitedHealth Group analyst ratings.
Delving into UnitedHealth Group's Background
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
A Deep Dive into UnitedHealth Group's Financials
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: UnitedHealth Group displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 9.8%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: UnitedHealth Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.74% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): UnitedHealth Group's ROE excels beyond industry benchmarks, reaching 6.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): UnitedHealth Group's ROA stands out, surpassing industry averages. With an impressive ROA of 2.07%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: UnitedHealth Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
